IP Library Granted Patent US 7,645,794
Granted Patent B2
US 7,645,794 · App. 11/853,277 · Granted Jan 12, 2010

Composition and method for increasing the anabolic state of muscle cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,794
App. No.
11/853,277
Granted
Jan 12, 2010
Kind
B2
Abstract

A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure.

Claims (16)

1. A composition for causing an anabolically-favorable state for muscle in a mammal, comprising from about 0.0001 g to about 0.75 g of ethyl pyruvate and from about 0.00001 g to about 0.75 g of at least one α-hydroxy branched-chain amino acid metabolite.

2. The composition of claim 1 , wherein the α-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.

3. The composition of claim 2 , wherein the amount of the ethyl pyruvate is about 0.001 g and the amount of the α-hydroxyisocaproic acid is about 0.0001 g.

4. The composition of claim 2 wherein the ethyl pyruvate and the α-hydroxy branched-chain amino acid metabolite are part of a solid oral dosage form having a multi-phasic rate of dissolution.

5. The composition of claim 4 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.

6. The composition of claim 5 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.

7. The composition of claim 5 , further comprising a third-phase, whereby said third-phase has a third rate of dissolution.

8. The composition of claim 7 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.

9. A method for causing an anabolically-favorable state of muscle in a mammal, comprising at least the step of administering to the mammal a and from about 0.00001 g to about 0.75 g at least one α-hydroxy branched-chain amino acid metabolite.

10. The method of claim 9 , wherein the α-hydroxy branched-chain amino acid metabolite is selected from the group consisting of α-hydroxyisocaproic acid, α-hydroxy-β-methylvaleric acid, and α-hydroxy-isovaleric acid.

11. The method of claim 10 , wherein the amount of the ethyl pyruvate is about 0.001 g; and the amount of the α-hydroxyisocaproic acid is about 0.0001 g.

12. The method of claim 10 wherein the ethyl pyruvate and the α-hydroxyisocaproic acid are part of a solid oral dosage form having a multi-phasic rate of dissolution.

13. The method of claim 12 wherein said multi-phasic rate of dissolution comprises a first-phase and a second-phase; whereby said first-phase has a first rate of dissolution said second-phase has a second rate of dissolution.

14. The method of claim 13 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.

15. The method of claim 13 , further comprising a third-phase, whereby said third-phase has a third rate of dissolution.

16. The method of claim 15 , wherein the multi-phasic rate of dissolution provides a time-release mechanism.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded May 29, 2026
From: ROYAL BANK OF CANADA
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 075647/0267 →
SECURITY AGREEMENT Recorded May 28, 2026
From: LOVATE HEALTH SCIENCES INTERNATIONAL INC.; NORTHERN INNOVATIONS HOLDING CORP.; LOVATE HEATH SCIENCES U.S.A. INC.
To: FGI WORLDWIDE LLC
Reel/Frame 075641/0893 →
MERGER AND CHANGE OF NAME Recorded Sep 30, 2024
From: ROYAL BANK OF CANADA; HSBC TRUST COMPANY (CANADA); HSBC MORTGAGE CORPORATION (CANADA); HSBC FINANCE MORTGAGES INC.; HSBC BANK CANADA + 4 OTHERS NOTED ABOVE IN 'CONVEYING PARTY DATA'
To: ROYAL BANK OF CANADA/BANQUE ROYALE DU CANADA
Reel/Frame 069072/0683 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER OF PATENT NUMBER 7,645,812 TO 7,465,812 PREVIOUSLY RECORDED AT REEL: 059662 FRAME: 0958. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Apr 26, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059793/0777 →
SECURITY INTEREST Recorded Apr 21, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059662/0958 →
CHANGE OF NAME Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS HOLDING CORP.
To: OLD NORTHERN INNOVATIONS CORP.
Reel/Frame 039672/0994 →
CHANGE OF NAME Recorded Aug 14, 2016
From: 2508304 ONTARIO LIMITED
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039673/0027 →
MERGER Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS HOLDING CORP.
To: OLD NORTHERN INNOVATIONS CORP.
Reel/Frame 039427/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2016
From: OLD NORTHERN INNOVATIONS CORP.
To: 2462096 ONTARIO LIMITED
Reel/Frame 039427/0313 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2016
From: OLD NORTHERN INNOVATIONS CORP.
To: 2508304 ONTARIO LIMITED
Reel/Frame 039427/0326 →
MERGER Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS AND FORMULATIONS CORP.
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039672/0851 →
CHANGE OF NAME Recorded Aug 14, 2016
From: 2462096 ONTARIO LIMITED
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039672/0990 →
MERGER Recorded Mar 30, 2011
From: MULTI FORMULATIONS LTD
To: NORTHERN INNOVATIONS AND FORMULATIONS CORP
Reel/Frame 026050/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2007
From: MOLINO, MICHELE; MACDOUGALL, JOSEPH
To: MULTI FORMULATIONS LTD.
Reel/Frame 019879/0539 →